Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. Co. has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. Co.'s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. We show 61 historical shares outstanding datapoints in our IONS shares outstanding history coverage, used to compute IONS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IONS market cap history over the course of time is important for investors
interested in comparing IONS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IONS versus a peer is one thing; comparing
IONS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IONS can fluctuate over the course of history.
With this page we aim to empower investors researching IONS by allowing them to research the IONS market cap history. |
Free IONS Email Alerts:
Video: The Importance of Market Cap
